Literature DB >> 12809175

Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement.

G Murdolo1, P Lucidi, C Di Loreto, N Parlanti, A De Cicco, C Fanelli, G Perriello, D Mughetti, R Pippi, A Brozzetti, F Santeusanio, P De Feo.   

Abstract

Ghrelin, the endogenous ligand for the GH secretagogue-receptor (GHS-R), in addition to its GH-releasing action, has orexigenic and adipogenic properties. These characteristics make ghrelin a potential hormone involved in the pathogenesis of obesity. Ghrelin levels are decreased in obese humans and it is unknown whether this decrease is responsible for the blunted GH secretion reported in visceral obesity. Since only few data are available on the potential feedback regulation by GH on systemic ghrelin concentrations, it remains to be established whether the correction of circulating GH concentrations in obese individuals affects ghrelin concentrations. To answer this question, we measured plasma ghrelin levels after a week of administration of low doses of recombinant human GH (rhGH) in a randomized, double-blind, placebo (PL)-controlled trial. This study was originally designed to evaluate the effects of GH replacement on lipid kinetics in visceral obese men. Six adult men with abdominal/visceral obesity (age 42+/-3 yr, body weight 107 +/- 10 kg, BMI 33 +/- 1 kg/m2, waist circumference 111 +/- 3 cm, mean +/- SE) were evaluated in the basal state (BS) and after one week of treatment with subcutaneous bedtime injections of either PL, 2.5 (GH2.5) or 3.3 (GH3.3) pg/kg/die of rhGH. In comparison to BS either PL, GH2.5 or GH3.3 did not significantly modify circulating ghrelin concentrations (p = 0.77). In contrast, a significant increase of serum GH (p = 0.0028), IGF-I (p = 0.0033) and whole body rate of lipolysis (p = 0.038, GH2.5; p = 0.009, GH3.3) occurred, in comparison to BS or PL, after GH2.5 and GH3.3, without differences between the two treatments. These data demonstrate that in abdominal/visceral obese men a short-term treatment with very low doses of rhGH replacement, sufficient to augment the rate of lipolysis, do not modify circulating ghrelin levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12809175     DOI: 10.1007/BF03345164

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  Effects of arterial versus venous sampling on analysis of glucose kinetics in man.

Authors:  E A McGuire; J H Helderman; J D Tobin; R Andres; M Berman
Journal:  J Appl Physiol       Date:  1976-10       Impact factor: 3.531

2.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.

Authors:  D E Cummings; J Q Purnell; R S Frayo; K Schmidova; B E Wisse; D S Weigle
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

3.  Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy.

Authors:  J A Janssen; F M van der Toorn; L J Hofland; P van Koetsveld; F Broglio; E Ghigo; S W Lamberts; A Jan van der Lely
Journal:  Eur J Endocrinol       Date:  2001-12       Impact factor: 6.664

Review 4.  Clinical aspects of growth hormone deficiency in adults.

Authors:  H de Boer; G J Blok; E A Van der Veen
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

5.  Ghrelin strongly stimulates growth hormone release in humans.

Authors:  K Takaya; H Ariyasu; N Kanamoto; H Iwakura; A Yoshimoto; M Harada; K Mori; Y Komatsu; T Usui; A Shimatsu; Y Ogawa; K Hosoda; T Akamizu; M Kojima; K Kangawa; K Nakao
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

6.  Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion.

Authors:  Tomomi Shiiya; Masamitsu Nakazato; Masanari Mizuta; Yukari Date; Muhtashan S Mondal; Muneki Tanaka; Shin-Ichi Nozoe; Hiroshi Hosoda; Kenji Kangawa; Shigeru Matsukura
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

7.  Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.

Authors:  Y Date; M Kojima; H Hosoda; A Sawaguchi; M S Mondal; T Suganuma; S Matsukura; K Kangawa; M Nakazato
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

8.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

9.  Short-term treatment with low doses of recombinant human GH stimulates lipolysis in visceral obese men.

Authors:  Paola Lucidi; Natascia Parlanti; Federica Piccioni; Fausto Santeusanio; Pierpaolo De Feo
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

10.  Modest decrements in plasma glucose concentration cause early impairment in cognitive function and later activation of glucose counterregulation in the absence of hypoglycemic symptoms in normal man.

Authors:  P De Feo; V Gallai; G Mazzotta; G Crispino; E Torlone; G Perriello; M M Ventura; F Santeusanio; P Brunetti; G B Bolli
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

View more
  3 in total

1.  The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes.

Authors:  S M Pöykkö; O Ukkola; H Kauma; E Kellokoski; S Hörkkö; Y A Kesäniemi
Journal:  Diabetologia       Date:  2005-02-02       Impact factor: 10.122

Review 2.  Ghrelin: integrative neuroendocrine peptide in health and disease.

Authors:  James T Wu; John G Kral
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

3.  Circulating ghrelin in patients with gastric or colorectal cancer.

Authors:  Qi Huang; Yue-Zu Fan; Bu-Jun Ge; Qin Zhu; Zhi-Yuan Tu
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.